Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 8—August 2005

Research

Methicillin-resistant Staphylococcus aureus, Hawaii, 2000–2002

Fenfang Li*Comments to Author , Sarah Y. Park†, Tracy L. Ayers†, F. DeWolfe Miller*, Ralph MacFadden†, Michele Nakata†, Myra Ching Lee†, and Paul V. Effler†
Author affiliations: *University of Hawaii School of Medicine, Honolulu, Hawaii, USA; †Hawaii Department of Health, Honolulu, Hawaii, USA

Main Article

Table 3

Resistance patterns of MRSA isolates from pediatric and adult patients by clinical setting, Hawaii, 2000–2002*

Antimicrobial drug Pediatric patients
Adult patients
Outpatients
Inpatients
Outpatients
Inpatients
No. isolates tested* No. (%) resistant No. isolates tested* No. (%) resistant p value† No. isolates tested* No. (%) resistant No. isolates tested* No. (%) resistant p value†
Ciprofloxacin 604 11 (2) 110 10 (9) <0.01 1,502 545 (36) 1,305 1,071 (85) <0.01
Clindamycin 1,083 71 (7) 202 39 (19) <0.01 3,936 1,462 (37) 2,830 2,128 (75) <0.01
Erythromycin 1,092 261 (24) 203 78 (38) <0.01 4,018 2,186 (54) 2,859 2,412 (84) <0.01
Gentamicin 997 9 (1) 199 12 (6) <0.01 3,289 418 (13) 2,609 906 (35) <0.01
Levofloxacin 215 5 (2) 59 9 (16) <0.01 629 245 (39) 549 433 (79) <0.01
Rifampin 1,028 4 (0) 199 5 (3) <0.01 3,773 134 (4) 2,795 355 (13) <0.01
Tetracycline 812 27 (3) 178 16 (9) <0.01 3,414 667 (20) 2,622 976 (37) <0.01
Trimethoprim/sulfamethoxazole 1,092 1 (0) 203 2 (1) NS 4,035 199 (5) 2,862 278 (10) <0.01
Vancomycin 1,092 0 (0) 203 0 (0) NA 4,036 0 (0) 2,865 0 (0) NA

*The number of MRSA isolates tested against each antimicrobial drug varies in each laboratory because the drug panel used differed for each MRSA. MRSA, methicillin-resistant Staphylococcus aureus; NS, not significant; NA, not applicable.
†By chi-square test comparing outpatients to inpatients within each patient group. Fisher exact test was used for rifampin within the pediatric population.

Main Article

TOP